GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
The primary endpoints of the SWIFT-1 and SWIFT-2 studies were a reduction in the annualized rate of clinically significant exacerbations (asthma attacks) over 52 weeks. Positive headline data from the SWIFT-1 and SWIFT-2 studies showed that treatment with depemokimab resulted in statistically significant and clinically meaningful reductions in exacerbations over 52 weeks versus placebo. The safety profile of depemokimab was comparable to that of placebo across both studies. The data are being further analyzed and full results will be presented at an upcoming scientific congress. GSK's stock has risen 20% so far this year against a decline of 4.6% for the industry. Image Source: Zacks Investment Research Type II inflammation is responsible for severe asthma experienced by more than 80% of patients with this condition. Type II inflammation is typically identified by elevated levels of eosinophils (a type of white blood cell) and drives severe asthma exacerbation. Depemokimab is
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- ADHD Drug Shortage Could Worsen After Arrests Of 2 Telehealth Executives, CDC Warns [Forbes]Forbes
- ACTO ACQUIRES 4TH DOWN SOLUTIONS, BRINGING TOGETHER TWO INDUSTRY LEADERS [Yahoo! Finance]Yahoo! Finance
- Medincell Joins the Euronext Tech Leaders [Yahoo! Finance]Yahoo! Finance
- Medincell Publishes Its Consolidated Annual Financial Results [Yahoo! Finance]Yahoo! Finance
- Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Barclays PLC from $20.00 to $21.00. They now have an "overweight" rating on the stock.MarketBeat
TEVA
Earnings
- 5/8/24 - Miss
TEVA
Sec Filings
- 6/10/24 - Form 4
- 6/10/24 - Form 4
- 6/10/24 - Form 4
- TEVA's page on the SEC website